Background: Essential hypertension is a common clinical disease and a risk factor for cardiovascular and cerebrovascular diseases. Olmesartan medoxomil, amlodipine, and hydrochlorothiazide are commonly used antihypertensive drugs. The aim of this study was to establish a robust UPLC-MS/MS method for the simultaneous determination of olmesartan medoxomil, amlodipine, and hydrochlorothiazide in dog plasma. At the same time, the and release studies were conducted, and a preliminary correlation (IVIVC) evaluation was performed.

Methods: The bioequivalence experiment was conducted with a double-crossed design. Three major components were extracted and analyzed by UHPLC-MS/MS. With the MRM scan, olmesartan and amlodipine were quantified by fragment conversion (m/z 447.10→190.10) and (m/z 408.95→294.00) under positive ESI mode, while hydrochlorothiazide was quantified with fragment conversion (m/z 295.90→268.90) under negative ESI mode. The release studies were performed using a USP paddle, and the dissolution medium was chosen from pH 6.0 to pH 6.8 according to the BCS classification of compounds. The IVIVC was calculated using the Wagner-Nelson equation.

Results: The linear ranges of olmesartan, amlodipine, and hydrochlorothiazide in the plasma were 5.0-2500, 0.1-50, and 3.0-1500 ng/mL, respectively. All accuracies were within 3.8% of the target values, and the findings revealed that intra-day and inter-day accuracies were less than 12.1%. Moreover, the recoveries exceeded 88.3%, the matrix effect tests were positive, and the stability tests were positive. With the establishment of correlation, the distinguishable dissolution condition (pH 6.8) was selected as the predictable condition.

Conclusion: The established method was suitable for the preclinical pharmacokinetic study of tripartite drugs with strong specificity and high sensitivity. Through the evaluation of IVIVC, the connection between in vivo and drug testing was initially established.

Download full-text PDF

Source
http://dx.doi.org/10.2174/0113816128295265240613061905DOI Listing

Publication Analysis

Top Keywords

amlodipine hydrochlorothiazide
12
method simultaneous
8
simultaneous determination
8
dog plasma
8
dissolution condition
8
olmesartan medoxomil
8
medoxomil amlodipine
8
release studies
8
olmesartan amlodipine
8
quantified fragment
8

Similar Publications

The present study quantified simultaneous determination of the active components included in Valzomix HCT tablets are hydrochlorothiazide (HCT), valsartan (VAL), and amlodipine (AML). Two chemometric methods-continuous wavelet transform (CWT) and ratio subtraction (RS)-along with a rapid and effective spectrophotometric approach-which does not require preparatory separation-were used to do the analysis. The CWT approach applied the zero-crossing method to analyze several wavelet families and selected the Daubechies 2, Symlet 2, and Biorthogonal 1.

View Article and Find Full Text PDF

Background: High output is a common cause for readmission after new ileostomy creation. The loss of sodium leads to compensatory activation of the renin-angiotensin-aldosterone system (RAAS). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are first-line therapy for hypertension in the United States.

View Article and Find Full Text PDF

Retraction notice to "Simultaneous determination of hydrochlorothiazide, amlodipine, and telmisartan with spectrophotometric and HPLC green chemistry applications"[Chemosphere 303 (2022) 135074].

Chemosphere

February 2025

Department of Chemistry, Soongsil University, Seoul, 06978, South Korea; Department of Sustainable Engineering, Saveetha School of Engineering, SIMATS, Chennai, 602105, India; Department of Chemical Engineering, Quchan University of Technology, Quchan, Iran.

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/policies/article-withdrawal).

View Article and Find Full Text PDF

Hypertension is a common risk factor for cardiovascular disease. Pharmacogenomics, as a tool for personalized healthcare, helps in determining the optimal drug treatment based on the genome of individual patient. This study reports a 49-year-old male with acute cerebral infarction, pulmonary infection, extremely high-risk hypertension (grade3), type 2 diabetes, hyperhomocysteinemia, hyperlipidemia, and fatty liver.

View Article and Find Full Text PDF

Drug-induced hyponatraemia and possible related signals: Analysis of 659 cases reported to the Spanish Pharmacovigilance System and disproportionality analysis.

Med Clin (Barc)

December 2024

Centre for Research on Drug Safety (CESME), Department of Cell Biology, Histology, Pharmacology and Genetics, Faculty of Medicine, University of Valladolid (Centro de Estudios Sobre la Seguridad de los Medicamentos (CESME), Departamento de Biología Celular, Histología, Farmacología y Genética, Facultad de Medicina, Universidad de Valladolid), Valladolid, Spain; Research Group Pharmacogenetics, Cancer Genetics, Genetic Polymorphisms and Pharmacoepidemiology, University of Valladolid (GIR Farmacogenética, Genética del Cáncer, Polimorfismos Genéticos y Farmacoepidemiología, Universidad de Valladolid), Spain. Electronic address:

Article Synopsis
  • Hyponatraemia can adversely affect cognitive function and increase risks for falls, fractures, and even hospital mortality.
  • The objective of the study was to identify safety signals related to drug-induced hyponatraemia and analyze cases reported in the Spanish Pharmacovigilance System.
  • The analysis revealed 659 cases of suspected drug-induced hyponatraemia, with a significant increase over five years; most cases were serious, affecting primarily elderly women, and were commonly associated with diuretics and antidepressants.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!